Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors

Inclusion Criteria: * Proven NSCLC or pulmonary metastases from extra-thoracic primary tumor * Must be eligible for curative lung resection (lobectomy) * Tumor/lesion size will be a minimum of 10mm along the minor diameter * Willing to participate in all aspects of study protocol for duration of the study * Able to understand study requirements * Signs informed consent form Exclusion Criteria: * Any contraindication to bronchoscopy, for example: * Untreatable life-threatening arrhythmias. * Inability to adequately oxygenate the patient during the procedure. * Acute respiratory failure with hypercapnia (unless the patient is intubated and ventilated). * Recent myocardial infarction. * Previously diagnosed high-grade tracheal obstruction. * Uncorrectable coagulopathy * Known coagulopathy * Platelet dysfunction or platelet count \<100 x 10\^3 cells/mm3 * History of major bleeding with bronchoscopy * Suspected pulmonary hypertension: additional testing required, such as ECG * Moderate-to-severe pulmonary fibrosis * Severe emphysema (GOLD III/IV) or chronic obstructive pulmonary disease (COPD): additional testing and PI consent is required * Bullae \>5cm located within the same lobe of target tumor/lesion * Any other severe or life-threatening comorbidity that could increase the risk associated with bronchoscopic RFA * Ongoing systemic infection * Contraindications to general anesthesia * Inability to stop anticoagulants or antiplatelet agents prior to procedure as dictated by the protocol * Prior thoracic surgery on the same side of the lung as the targeted tumor/lesion * Breastfeeding women or females of childbearing potential with a positive pregnancy test prior to the procedure or the intent to become pregnant during the study * Life expectancy of less than one year.